Impact of Margin Status and Neoadjuvant Chemotherapy on Survival, Recurrence After Liver Resection for Colorectal Liver Metastasis
- 602 Downloads
This study was designed to determine the impact of positive margin and neoadjuvant chemotherapy (NAC) on recurrence and survival after resection of colorectal liver metastasis (CRLM).
Prospective analysis of 1,255 patients undergoing resection of CLRM was undertaken. The impact of NAC, site of recurrence, and survival between R0 and R1 groups was analysed.
The R0 and R1 resection rates were 68.9 % (n = 865) and 31.1 % (390). The median OS for R0 group was 2.7 years (95 % CI 2.56–2.85) and R1 group 2.28 years (CI 2.06–2.52; P < 0.001). The median DFS for R0 group was 1.52 years (CI 1.38–1.66) and R1 group 1.04 years (CI 0.94–1.19; P < 0.001). The intrahepatic recurrence was higher in R1 group 132 (33.8 %) versus 142 (16.4 %) [P = 0.0001]. A total of 103 (11.9 %) patients in R0 group underwent redo liver resection for recurrence compared with 66 (16.9 %) patients in R1 group (P = 0.016). NAC did not impact recurrence rate (57.8 % vs. 61.5 %, P = 0.187) and redo liver surgery between R0 and R1 groups (13 % vs. 17 %, P = 0.092). Within the R1 group, the intrahepatic recurrence rates were similar with and without NAC (33.9 % vs. 33.7 %, P = 0.669). However, DFS was longer in the no chemotherapy group than the chemotherapy group.
R1 resections increase the likelihood of recurrence in the liver and redo liver surgery. NAC does not seem to improve survival in margin positive patients or have an impact on recurrence or reduce need for redo liver surgery for recurrence. In patients with R1 resection, neoadjuvant chemotherapy may have adverse outcome on disease free survival.
KeywordsLiver Resection Colorectal Liver Metastasis Margin Status Future Liver Remnant Chemotherapy Group
- 3.Spelt L, Andersson B, Nilsson J, Andersson R. Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review. Ann Surg. 2012;38(1):16–24. Epub 2011/11/15.Google Scholar
- 8.van Dam RM, Lodewick TM, van den Broek MA, de Jong MC, Greve JW, Jansen RL, et al. Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB (Oxford). 2014;16(6):550–9. Epub 2013/11/20. Google Scholar
- 9.Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16. Epub 2008/03/25.PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Figueras J, Burdio F, Ramos E, Torras J, Llado L, Lopez-Ben S, et al. Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections. Ann Oncol. 2007;18(7):1190–5. Epub 2007/04/17.PubMedCrossRefGoogle Scholar
- 23.Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–40.PubMedCrossRefGoogle Scholar